Abstract Life expectancy of the children affected with Spinal Muscular Atrophy (SMA), an autosomal recessive hereditary disease, is considerably reduced by the onset of the respiratory problems induced by the scoliosis. It is hypothesized that maintaining walking would significantly reduce or delay the appearance of related complications, which would increase life expectancy and in addition would improve the quality of life. This paper presents the challenges and main features of the ATLAS 2020, an active paediatric exoskeleton developed in the frame of the EXOtrainer project. The result of the evaluation of ATLAS 2020 exoskeleton in the clinical trials performed in the hospital Sant Joan de Deu in Barcelona (Spain) during three months are summarized. This evaluation was carried out with 7 children with Spinal Muscular Atrophy (SMA). The study evaluates the performance and safety of the exoskeleton from psychological and physiological perspective. The evaluation was successfully passed. ATLAS 2020 gait trainer exoskeleton is expected to reduce and delay the side effect of the disease and increase these children’s quality of life.
EXOtrainer Project Clinical Evaluation of Gait Training with Exoskeleton in Children with Spinal Muscular Atrophy
Advances in Robotics Research: From Lab to Market ; 2 ; 211-227
Springer Tracts in Advanced Robotics ; 132 , 2
2019-09-18
17 pages
Aufsatz/Kapitel (Buch)
Elektronische Ressource
Englisch
MUNE in spinal muscular atrophy
British Library Conference Proceedings | 2003
|MUNE in prior poliomyelitis and spinal muscular atrophy
British Library Conference Proceedings | 2003
|Gait training using a robotic hip exoskeleton improves metabolic gait efficiency in the elderly
BASE | 2019
|